Skip to content

Strong Buy Consensus

Goldman Sees This As The More Important Factor For Stocks – And Upside Potential In These 2 Therapeutics Companies

How important a factor is the outcome of the presidential election for the direction of stocks? Not as important as a COVID-19 vaccine, according to Goldman Sachs. With this in mind, today’s article highlights two therapeutics companies focused on battling neurodegenerative diseases where analysts at Goldman see significant upside potential. For these two stocks – both of which have earned… 

CLICK HERE »Goldman Sees This As The More Important Factor For Stocks – And Upside Potential In These 2 Therapeutics Companies

Cash In On This “Strong Buy” NASH Stock

In the wake of two seemingly negative events, shares of the nonalcoholic steatohepatitis (NASH) drug developer focused on in today’s article experienced a sharp sell-off at the end of last week, but one analyst is imploring investors to “view last week’s weakness as a prime buying opportunity” – and sees massive upside potential of 210%. For more on this stock… 

CLICK HERE »Cash In On This “Strong Buy” NASH Stock